Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Changes in Stockholders Equity

v3.22.2
Unaudited Condensed Consolidated Statements of Changes in Stockholders Equity - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Common Shares Issuable [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Non-Controlling Interests [Member]
Total
Balance at Dec. 31, 2020 $ 3 $ 95   $ 583,000 $ (482,760) $ 96,661 $ 196,999
Balance (in shares) at Dec. 31, 2020 3,427,138 94,877,492          
Stock-based compensation expense       8,123     8,123
Issuance of common stock related to equity plans   $ 2   (2)      
Issuance of common stock related to equity plans (in shares)   2,558,645          
Issuance of common stock under ESPP       137     137
Issuance of common stock under ESPP (in shares)   59,107          
Preferred A dividends declared and paid       (4,015)     (4,015)
Partner company's at-the-market offering, net       97,332     97,332
Issuance of common stock under partner company's ESPP       158     158
Partner company's dividends declared and paid       (375)     (375)
Common shares issuable for dividend on partner company's convertible preferred shares     $ 263       263
Issuance (reversal) of partner company's common shares for research and development expenses       129     129
Partner company's exercise of options for cash       7     7
Non-controlling interest in partner companies       (81,459)   81,459  
Net loss attributable to non-controlling interest           (38,100) (38,100)
Net loss attributable to common stockholders         (12,357)   (12,357)
Balance at Jun. 30, 2021 $ 3 $ 97 263 603,035 (495,117) 140,020 248,301
Balance (in shares) at Jun. 30, 2021 3,427,138 97,495,244          
Balance at Mar. 31, 2021 $ 3 $ 97   597,384 (491,582) 138,323 244,225
Balance (in shares) at Mar. 31, 2021 3,427,138 97,263,054          
Stock-based compensation expense       4,350     4,350
Issuance of common stock related to equity plans (in shares)   173,083          
Issuance of common stock under ESPP       137     137
Issuance of common stock under ESPP (in shares)   59,107          
Preferred A dividends declared and paid       (2,008)     (2,008)
Partner company's at-the-market offering, net       25,910     25,910
Partner company's dividends declared and paid       (188)     (188)
Common shares issuable for dividend on partner company's convertible preferred shares     263       263
Issuance (reversal) of partner company's common shares for research and development expenses       3     3
Non-controlling interest in partner companies       (22,553)   22,553  
Net loss attributable to non-controlling interest           (20,856) (20,856)
Net loss attributable to common stockholders         (3,535)   (3,535)
Balance at Jun. 30, 2021 $ 3 $ 97 $ 263 603,035 (495,117) 140,020 248,301
Balance (in shares) at Jun. 30, 2021 3,427,138 97,495,244          
Balance at Dec. 31, 2021 $ 3 $ 101   656,033 (547,463) 117,203 225,877
Balance (in shares) at Dec. 31, 2021 3,427,138 101,435,505          
Stock-based compensation expense       10,644     10,644
Issuance of common stock related to equity plans   $ 3   (3)      
Issuance of common stock related to equity plans (in shares)   2,646,375          
Issuance of common stock under ESPP       99     99
Issuance of common stock under ESPP (in shares)   135,464          
Issuance of common stock for at-the-market offering, net   $ 4   5,523     5,527
Issuance of common stock for at-the-market offering, net (in shares)   3,500,303          
Preferred A dividends declared and paid       (4,016)     (4,016)
Partner company's at-the-market offering, net       14,476     14,476
Issuance of common stock under partner company's ESPP       116     116
Partner company's dividends declared and paid       (375)     (375)
Partner company's net settlement of shares withheld for taxes       (1,698)     (1,698)
Partner company's warrants issued in conjunction with debt       384     384
Issuance (reversal) of partner company's common shares for research and development expenses       (35)     (35)
Partner company's exercise of options for cash       111     111
Non-controlling interest in partner companies       (19,568)   19,568  
Net loss attributable to non-controlling interest           (66,292) (66,292)
Net loss attributable to common stockholders         (37,116)   (37,116)
Balance at Jun. 30, 2022 $ 3 $ 108   661,691 (584,579) 70,479 147,702
Balance (in shares) at Jun. 30, 2022 3,427,138 107,717,647          
Balance at Mar. 31, 2022 $ 3 $ 106   660,973 (563,223) 95,719 193,578
Balance (in shares) at Mar. 31, 2022 3,427,138 106,321,875          
Stock-based compensation expense       5,081     5,081
Issuance of common stock related to equity plans (in shares)   176,406          
Issuance of common stock under ESPP       99     99
Issuance of common stock under ESPP (in shares)   135,464          
Issuance of common stock for at-the-market offering, net   $ 2   1,299     1,301
Issuance of common stock for at-the-market offering, net (in shares)   1,083,902          
Preferred A dividends declared and paid       (2,008)     (2,008)
Partner company's at-the-market offering, net       3,693     3,693
Partner company's dividends declared and paid       (188)     (188)
Issuance (reversal) of partner company's common shares for research and development expenses       (35)     (35)
Partner company's exercise of options for cash       111     111
Non-controlling interest in partner companies       (7,334)   7,334  
Net loss attributable to non-controlling interest           (32,574) (32,574)
Net loss attributable to common stockholders         (21,356)   (21,356)
Balance at Jun. 30, 2022 $ 3 $ 108   $ 661,691 $ (584,579) $ 70,479 $ 147,702
Balance (in shares) at Jun. 30, 2022 3,427,138 107,717,647